Study to Evaluate the Effects of a Formula on the Gut Health of Healthy Chinese Infants and Young Children

NCT ID: NCT04864665

Last Updated: 2023-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

455 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-12

Study Completion Date

2023-10-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The infant gut microbiota, a major driver of the maturation of the immune system, is formed through the successive establishment and development during infancy and early childhood. It can inhibit the growth of pathogenic bacteria, prevent the occurrence of diseases and improve the child's quality of life. It is therefore important to regulate the microbiota balance in infants and young children.

This objective of this post-launch study is to evaluate the effects of a formula with prebiotics and milk fat on the gut microbiota and stool characteristics of healthy Chinese infants and young children. The duration of the study for each participant is 32 days and includes 3 study visits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

interventional with breastfed reference group
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Formula fed

0 - 6 months: a formula with prebiotics and milk fat (Stage 1); \>6 - 12 months: a formula with prebiotics and milk fat (Stage 2); \>1 - 2 years: a formula with prebiotics and milk fat (Stage 3)

Group Type EXPERIMENTAL

a formula with prebiotics and milk fat

Intervention Type DIETARY_SUPPLEMENT

Provided in a formula added with prebiotics and milk fat for 1 month

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

a formula with prebiotics and milk fat

Provided in a formula added with prebiotics and milk fat for 1 month

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The gestational age was 37-42 weeks at birth;
* Birth weight ≥2,500 g and ≤ 4,500 g;
* Chinese nationality;
* Weight and height are within normal range (i.e. WHO Child Growth Standards

* 2SD);
* No relocation across provinces/ cities in the past 1 year and no plans to relocate during the study period.
* Breastfeeding reference: breastfeeding at the time of enrollment, and the mother intends to continue breastfeeding throughout the study period;
* Intervention arm: formula feeding / habitual milk drinking (formula milk, milk and other dairy products) at the time of enrollment, and willing to change from the original milk powder / dairy product to the study formula, and consume it as instructed during the study period;
* The child's parent(s) / guardian has access to a mobile phone on which the secure digital WeChat platform can be installed and used, connect to the network, take photographs and record defecation, and complete questionnaires during the study;
* The child's parent(s) / guardian is of legal age of consent, has sufficient command of Chinese (Mandarin) language to complete the informed consent and other study documents, is willing and able to fulfill the requirements of the study.
* The child's parent(s) / guardians can be contacted directly by telephone or WeChat;

Exclusion Criteria

* Neonatal asphyxia at birth;
* Chronic infectious, metabolic, genetic illness or other disease including any condition that impacts feeding or may impact study outcomes;
* Cognitive and developmental disorders;
* Antibiotic usage up to 2 weeks before enrollment;
* Ongoing antibiotic treatment;
* Taking probiotic supplements or formula with probiotics up to 1 month before enrollment;
* Participation in other clinical trials;
* Parent(s)' / guardian's refusal to participate in the study;
* Known or suspected allergy to cow milk, soy or fish
Maximum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nutricia Early Life Nutrition (Shanghai) Co., Ltd

UNKNOWN

Sponsor Role collaborator

Danone Nutricia

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guangzhou Women and Children's Medical Center

Guangzhou, Guangdong, China

Site Status

Zhengzhou Children's hospital of Henan Children's hospital

Zhengzhou, Henan, China

Site Status

Tangdu Hospital, The Fourth Military Medical University

Xi’an, Shanxi, China

Site Status

Chengdu Women's and Children's Central Hospital

Chengdu, Sichuan, China

Site Status

Ningbo Women and Children's Hospital

Ningbo, Zhejiang, China

Site Status

Beijing Children's Hospital of Capital Medical University

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SBB0E_34098

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotic Formula and Infant Growth
NCT01476397 COMPLETED NA